# Phase 2 pancreatic cancer trials recruiting: 128 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 128 trials in phase 2 for pancreatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 pancreatic cancer trials: 128 rows for $6.40, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/pancreatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 128
- Recruiting or not yet: 128
- Read on: November 19, 2026

## Trials

The 25 newest of 128, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 26, 2026 | NCT07895498 | A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Pancreatic Cancer, Skin Toxicities | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895498) |
| October 13, 2026 | NCT07871461 | Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates... | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 2 | Not yet recruiting | Pancreatic Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871461) |
| October 8, 2026 | NCT07864571 | Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Pancreatic Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864571) |
| September 22, 2026 | NCT07833241 | Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833241) |
| September 18, 2026 | NCT07828756 | Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828756) |
| September 17, 2026 | NCT07825753 | Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | Fudan University | Phase 2 | Not yet recruiting | Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC) | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825753) |
| September 11, 2026 | NCT07814859 | Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic... | The First Affiliated Hospital of Zhengzhou University | Phase 2 | Not yet recruiting | Pancreatic Cancer | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814859) |
| September 10, 2026 | NCT07814066 | A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With... | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Pancreatic Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814066) |
| September 3, 2026 | NCT07802418 | Molecularly Tailored Therapy in Advanced Pancreatic Cancer | Herlev Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802418) |
| August 25, 2026 | NCT07784374 | A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable... | Genfleet Therapeutics (Shanghai) Inc. | Phase 2 | Recruiting | Pancreatic Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784374) |
| August 19, 2026 | NCT07773363 | Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer | Tang-Du Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773363) |
| August 14, 2026 | NCT07765836 | Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | Massachusetts General Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer Metastatic | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765836) |
| August 4, 2026 | NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With... | Ruijin Hospital | Phase 2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung Neoplasms | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745790) |
| July 9, 2026 | NCT07691593 | Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer | Changhai Hospital | Phase 2 | Not yet recruiting | Pancreatic Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691593) |
| July 8, 2026 | NCT07689955 | A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer | Royal Marsden NHS Foundation Trust | Phase 2 | Not yet recruiting | Pancreatic Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689955) |
| July 6, 2026 | NCT07683221 | SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer | Shandong Cancer Hospital and Institute | Phase 2 | Recruiting | Pancreatic Cancer | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683221) |
| June 12, 2026 | NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Verastem, Inc. | Phase 2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644559) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| June 5, 2026 | NCT07629609 | BEFAST Study, \[68Ga\]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Pancreatic Cancer, Adult, Gastroesophageal Cancer (GC) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629609) |
| May 20, 2026 | NCT07600268 | Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced... | Shandong Cancer Hospital and Institute | Phase 2 | Recruiting | Pancreatic Cancer Non-resectable | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600268) |
| May 15, 2026 | NCT07589569 | An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer | Shandong Suncadia Medicine Co., Ltd. | Phase 2 | Recruiting | Pancreatic Cancer | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589569) |
| May 14, 2026 | NCT07586813 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586813) |
| May 11, 2026 | NCT07578337 | A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for... | Nelum Corp | Phase 2 | Not yet recruiting | Untreated, Advanced Pancreatic Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578337) |
| April 21, 2026 | NCT07542002 | Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or... | Ningbo Medical Center Lihuili Hospital | Phase 2 | Recruiting | Pancreatic Cancer | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542002) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 7 |
| Shanghai Zhongshan Hospital | 6 |
| Shandong Cancer Hospital and Institute | 4 |
| Ruijin Hospital | 4 |
| Changhai Hospital | 3 |
| Mayo Clinic | 3 |
| Zhejiang University | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 2 |
| National Cancer Institute (NCI) | 2 |
| RenJi Hospital | 2 |
| Medical College of Wisconsin | 2 |
| Massachusetts General Hospital | 2 |
| Minia University | 2 |
| [Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical) | 2 |
| Sun Yat-sen University | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| Tang-Du Hospital | 1 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Royal Marsden NHS Foundation Trust | 1 |
| Washington University School of Medicine | 1 |
| Herlev Hospital | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 56 |
| United States | 40 |
| South Korea | 7 |
| Australia | 6 |
| Canada | 6 |
| France | 6 |
| Spain | 6 |
| Denmark | 5 |
| Italy | 4 |
| Japan | 4 |
| Belgium | 3 |
| Germany | 3 |
| United Kingdom | 3 |
| Norway | 2 |
| Egypt | 2 |
| Singapore | 2 |
| Hungary | 2 |
| Taiwan | 2 |
| Hong Kong | 1 |
| Ireland | 1 |
| Puerto Rico | 1 |
| Israel | 1 |
| Georgia | 1 |
| Netherlands | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Machinery and tool manufacturers in the United States](https://specstream.ai/data/businesses/machinery-and-tool-manufacturers/united-states)
- [Crane services in the United States](https://specstream.ai/data/businesses/crane-services/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
- [Door suppliers in the United States](https://specstream.ai/data/businesses/door-suppliers/united-states)
- [Web design firms in the United States](https://specstream.ai/data/businesses/web-design-firms/united-states)
